Aligned Health Ventures

www.alignedhealth.ventures

VCMatch tracks Aligned Health Ventures as an investor focused on AI/ML, Digital Health, and Healthtech companies, Seed rounds, and United States markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed

Focus Areas

AI/ML, Digital Health, Healthtech

Geography

United States

Investment Thesis

Aligned Health Ventures targets seed-stage, AI-native healthcare companies that address a concentrated, high-cost portion of U.S. healthcare (chronic disease, behavioral health, metabolic syndrome, maternal health). The firm believes the seed window is when clinical assumptions, data architecture, and outcome measurement frameworks are established, so investors at seed “shape whether a company is built to prove what it claims.” AHV combines a mission-first discipline with expectations for market-rate returns by requiring rigorous outcome measurement, regulatory and data governance diligence, and a focus on durable clinical endpoints and payer-readiness.

Is Aligned Health Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Aligned Health Ventures is most relevant for founders raising Seed rounds in AI/ML, Digital Health, and Healthtech, especially across United States.

Focus statement

AHV invests at seed in health AI companies that address conditions with high morbidity burden and concentrated cost, prioritizing clear clinical endpoints, measurable outcome trajectories, and a durable reason to exist beyond reimbursement dynamics.

Value Add

Seed-stage specialization meant to "shape whether a company is built to prove what it claims" — investing where clinical assumptions and data architecture are still being formed.
Explicit prioritization framework: "We prioritize conditions by morbidity burden and cost concentration before evaluating technology."
Rigorous algorithmic and regulatory diligence: diligence includes "algorithmic transparency, bias evaluation, FDA and CMS pathway viability, and data governance posture."
Foundation-eligible capital at seed: "AHV has received independent legal confirmation of its eligibility to receive Program Related Investments from private foundations and Mission Related Investments from mission-aligned institutional investors" — enabling foundation capital at seed stage.
BoardKit governance product deployed at investment: "BoardKit...creates institutionally auditable board governance from day one," accelerating portfolio readiness for Series A, acquirers, and health system partners.